Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2023 | Current trials of interest in CLL

Barbara Eichhorst • 7 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Antibodies BTK inhibitors Obinutuzumab Pirtobrutinib Venetoclax
MAJIC

In this interview, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, highlights trials of interest in the field of chronic lymphocytic leukemia (CLL) treatment – the Phase III CLL18 trial beginning at the end of 2024 and the MAJIC trial (NCT05057494). This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Barbara Eichhorst

Optimizing frontline therapy in CLL: triplet regimens and testing for MRD 1:49
Optimizing frontline therapy in CLL: triplet regimens and testing for MRD
Barbara Eichhorst • 14 Sep 2025
Practical considerations for physicians managing patients with CLL in the frontline setting 0:59
Practical considerations for physicians managing patients with CLL in the frontline setting
Barbara Eichhorst • 14 Sep 2025
A session on the management of treatment lines throughout the course of CLL 1:33
A session on the management of treatment lines throughout the course of CLL
Barbara Eichhorst • 14 Sep 2025
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1 1:37
Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1
Barbara Eichhorst • 14 Sep 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals